DS Healthcare Group Reports Third Quarter 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DS Healthcare Group Reports Third Quarter 2014 Financial Results As Company Reaches EBITDAS Profitability

Pompano Beach, Fla., Nov. 17, 2014 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products, today announced financial results for the three and nine months ended September 30, 2014.

Q3 2014 Highlights:

·      Net revenues were $3,278,000, up 2.4% over Q3 2013

·      Gross margins increase to 75.1% from 55.1% in Q3 2013

·      Gross profits increase to $2,464,000 up 39.8% over Q3 2013

·      Net loss narrows 94.8% to $(54,000) from Q3 2013

·      Adjusted EBITDAS, a non-GAAP financial measure resulted in a net gain of $94,000 from a loss of $(777,865) in Q3 2013

"The 20 points improvement in gross margin that we've achieved during the quarter reflects our solid execution on the goals we set in an effort to focus on and improve our profitability. As we continue to effectively address our operating efficiencies, the filling and shipping of open orders will experience a quicker turn around, and we believe this will significantly increase our domestic revenues. Our international sales growth is currently driven by our Mexican subsidiary which posted a 24% increase in the third quarter of 2014 over the third quarter of 2013. As more regulatory licenses are granted for our products in other international markets, we expect a greater increase in international sales. We look forward to closing out a strong year and have over $2.9 million in orders so far this quarter and are on track to deliver on our revenue target for 2014 that is in-line with our 6-year historical yearly revenue increase, thereby establishing strong momentum to carry us into 2015," stated DS Healthcare President and CEO Daniel Khesin.

"Our efforts to become profitable are paying off and we believe that we have turned an important corner and are positioned to continue to show improved profitability in the coming quarters," Khesin concluded.

Net revenues were $3,278,117 for the three months ended September 30, 2014, an increase of 2.4% over revenues of $3,200,189 in the year-earlier period. Revenue growth in the third quarter was driven by higher sales from the Company's Mexican subsidiary. This growth was partially offset by a reduction in domestic sales due to $1 million in open orders that are scheduled for delivery during the fourth quarter.

Gross margin increased to 75.1% in the third quarter of 2014 from 55.1% in the same quarter of the prior year. This dramatic increase was a result of several factors including production efficiencies, improved pricing from suppliers, and strategic cost cutting efforts. Gross profits were up 39.8% to $2,464,446 in the third quarter of 2014, as compared to $1,762,426 in the year-earlier period. Selling and marketing costs decreased by 22.8% to $912,345 in the recent quarter from $1,181,897 in the same period last year. General and administrative costs increased by 22.5% to $1,668,807, as compared to $1,362,341 in the same period of 2013. DS Healthcare's net loss narrowed by 94.8% to $(54,496) or $(0.00) per share in the third quarter of 2014 from $(1,053,406) or $(0.08) in the same period of 2013. On an adjusted EBITDAS basis, a non-GAAP financial measure, the third quarter of 2014 resulted in a gain of $94,018 compared to a loss of $(777,865) in the year-earlier period.

For the nine months ended September 30, 2014 net revenues were $9,707,504, a 8.4% decline from revenues of $10,593,035 for the nine months ended September 30, 2013. Net revenue growth by the Company's Mexican subsidiary was offset by a decrease in sell-through in foreign markets due to pending regulatory licensing and a decline in recorded domestic sales due to backorders that were pending completion and shipments.

Gross margin increased to 60.7% in the first nine months of 2014 from 48.5% in the same period of the prior year, as a result of improved production efficiencies, improved cost from suppliers, and cost cutting efforts including payroll. Gross profits were up 12% to $5,888,426 in the first nine months of 2014, as compared to $5,138,195 in the first nine months of 2013. Selling and marketing costs increased by 8.6% to $3,076,605 in the nine months ended September 30, 2014 from $2,833,262 in the same period last year. General and administrative costs increased by 2.4% to $4,341,287 in the first nine months of 2014, as compared to $4,240,575 in the same period of 2013. DS Healthcare's net loss decreased by 32.4% to $(1,533,617) or $(0.10) per share in the first nine months of 2014 from $(2,268,463) or $(0.19) per share in the same period of 2013. 

On September 30, 2014 the Company had cash and cash equivalents of $493,947 and working capital of $3,306,741. Total stockholders' equity on September 30, 2014 was $4,863,008.

Adjusted EBITDAS

We believe Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation ("Adjusted EBITDAS"), a non-GAAP financial measure, is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary for different companies for reasons unrelated to overall operating performance. We believe that:

·      Adjusted EBITDAS provides investors and other users of our financial information consistency and comparability with our past financial performance, facilitates period-to-period comparisons of operations and facilitates comparisons with other companies, many of which use similar non-GAAP financial measures to supplement their GAAP results; and

·      Adjusted EBITDAS is useful because it excludes non-cash charges, such as depreciation and amortization, stock-based compensation and one-time charges, which the amount of such expense in any specific period may not directly correlate to the underlying performance of our business operations and these expenses can vary significantly between periods

 

We use Adjusted EBITDAS in conjunction with traditional GAAP measures as part of our overall assessment of our performance, to evaluate the effectiveness of our business strategies and to communicate with our lenders, stockholders and board of directors concerning our financial performance.

Adjusted EBITDAS should not be considered as a substitute for other measures of financial performance reported in accordance with GAAP. There are limitations to using non-GAAP financial measures, including that other companies may calculate these measures differently than we do. We compensate for the inherent limitations associated with using Adjusted EBITDAS through disclosure of these limitations, presentation of our financial statements in accordance with GAAP and reconciliation of Adjusted EBITDAS to the most directly comparable GAAP measure, specifically net loss.

The following provides a reconciliation of net loss to Adjusted EBITDAS:

        30-Sep-14 30-Sep-14  
         3 mos  9 mos  
             
Net Loss        (54,496)  (1,539,821)  
Non-GAAP adjustments:          
Interest expense, net      8,888  58,876  
Taxes        (13,332)  18,194  
Depreciation and amortization      67,006  192,081  
Stock-based compensation      85,952  492,805  
Adjusted EBITDAS      94,018  (777,865)  
             

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group's flagship brand, visit www.dslaboratories.com

Forward-looking statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov .

Laurel Moody Corporate Profile 1.646.810.0608

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 128

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 197

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 107

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 37

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 212

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 237

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading

Top 5 Most Recently Viewed Articles

Tarkett Updates on Voting Rights and Share Capital Structure

Updated Category News Views 57

Tarkett's Current Voting Rights and Share Capital The information regarding Tarkett’s share capital and the total number of voting rights reflects vital details for investors and stakeholders. As of the designated date, Tarkett boasts a significant total number of shares that contribute to its economic activities. Understanding Voting Rights in Tarkett As a significant...

Continue Reading
Quiddity Engineering Welcomes Ryan Quinn as New GM in Texas

Updated Category News Views 267

Quiddity Engineering Introduces Ryan Quinn, PE, as General Manager Quiddity Engineering is thrilled to share the news of Ryan Quinn, PE, joining the team as the General Manager for its Central Texas region. This appointment signifies a key strategic move for the organization, as Ryan brings over 18 years of invaluable experience in the consulting engineering landscape....

Continue Reading
Pure Roofing Unveils Innovative Office Space Focused on Growth

Updated Category News Views 206

Pure Roofing Launches New Office to Elevate Employee Culture Pure Roofing has recently expanded by opening a new office, reflecting a commitment to employee well-being and community engagement. Featuring a unique design that includes an indoor basketball court, this innovative space aims to enhance teamwork, productivity, and wellness among staff. The establishment of...

Continue Reading
Crown Point Energy Reports Q3 Financial Performance Highlights

Updated Category News Views 207

Crown Point Energy Announces Financial Results for Q3 Crown Point Energy Inc. recently shared its operating and financial results for the period ending September 30, 2024. These insights reflect the company’s performance amidst varied market conditions. Financial Overview of Q3 2024 In Q3 2024, Crown Point faced several challenges but also solid achievements: Reported a...

Continue Reading
Empowering Financial Innovation: Semifinalists of 2024 Edition

Updated Category News Views 125

Milken-Motsepe Prize in FinTech Announces Semifinalists The Milken Institute and the Motsepe Foundation have revealed the 10 standout teams that have advanced to the Semifinalist Round of the prestigious Milken-Motsepe Prize in FinTech, each securing $100,000 in funding to fuel their innovative projects. Driving Financial Inclusion Through Innovation This esteemed prize...

Continue Reading